The company states: “Artelo Biosciences (ARTL) announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo’s development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 Inhibitors as Novel Therapeutics (featuring ART26.12); ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia; ART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex(R) in Rats.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Reports Q3 2024 Financials and Progress
- Artelo Biosciences announces new data on novel non-opioid treatment for OA pain
- Artelo Biosciences reports Q3 EPS (35c), consensus (46c)
- Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
- Is ARTL a Buy, Before Earnings?